This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly mCRPCT (metastatic castration-resistant cancer). describes widely used Radium-223 and novel trend TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion growing PSMA-based therapy, we aim also to analyze most useful diag...